FDA approves darolutamide

On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for...

Amy Lightner MD – 682593

Recipient: Recipient Name Amy Lightner, MD Amy Lightner MD 604 Beardsley LaneAudtin, TX 78746United States amylightner8@gmail.com Issuing Office: Center for Biologics Evaluation and Research (CBER) United States Secondary Issuing Offices Dear Dr. Lightner:The Food and...